Aberdeen Group plc grew its holdings in shares of Krystal Biotech, Inc. (NASDAQ:KRYS – Free Report) by 190.9% in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 108,518 shares of the company’s stock after purchasing an additional 71,217 shares during the quarter. Aberdeen Group plc owned approximately 0.38% of Krystal Biotech worth $14,917,000 as of its most recent filing with the Securities & Exchange Commission.
Several other hedge funds and other institutional investors have also recently made changes to their positions in the business. EP Wealth Advisors LLC purchased a new stake in Krystal Biotech in the 1st quarter worth approximately $473,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in Krystal Biotech by 173.8% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 575,506 shares of the company’s stock worth $103,764,000 after acquiring an additional 365,304 shares in the last quarter. S Squared Technology LLC increased its holdings in Krystal Biotech by 2.1% in the 1st quarter. S Squared Technology LLC now owns 97,215 shares of the company’s stock worth $17,528,000 after acquiring an additional 2,000 shares in the last quarter. Tempus Wealth Planning LLC purchased a new stake in Krystal Biotech in the 2nd quarter worth approximately $327,000. Finally, Fifth Third Bancorp increased its holdings in Krystal Biotech by 159.1% in the 1st quarter. Fifth Third Bancorp now owns 171 shares of the company’s stock worth $31,000 after acquiring an additional 105 shares in the last quarter. Hedge funds and other institutional investors own 86.29% of the company’s stock.
Analyst Upgrades and Downgrades
Several equities research analysts recently issued reports on KRYS shares. Bank of America reduced their target price on shares of Krystal Biotech from $193.00 to $192.00 and set a “buy” rating for the company in a report on Tuesday, July 22nd. Weiss Ratings reissued a “hold (c)” rating on shares of Krystal Biotech in a report on Wednesday, October 8th. HC Wainwright reissued a “buy” rating and issued a $240.00 target price on shares of Krystal Biotech in a report on Monday, September 15th. Chardan Capital dropped their price target on Krystal Biotech from $219.00 to $216.00 and set a “buy” rating for the company in a research note on Friday, August 22nd. Finally, Citigroup restated a “neutral” rating and issued a $166.00 price target (down from $176.00) on shares of Krystal Biotech in a research note on Tuesday, August 5th. Six equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $209.00.
Krystal Biotech Stock Performance
NASDAQ KRYS opened at $188.05 on Wednesday. The company has a market capitalization of $5.44 billion, a P/E ratio of 38.22 and a beta of 0.64. Krystal Biotech, Inc. has a one year low of $122.80 and a one year high of $207.84. The stock has a 50 day moving average price of $157.48 and a 200-day moving average price of $151.04.
Krystal Biotech (NASDAQ:KRYS – Get Free Report) last posted its earnings results on Monday, August 4th. The company reported $1.29 EPS for the quarter, beating analysts’ consensus estimates of $1.08 by $0.21. The firm had revenue of $96.04 million during the quarter, compared to the consensus estimate of $95.42 million. Krystal Biotech had a return on equity of 15.21% and a net margin of 40.85%. As a group, equities analysts predict that Krystal Biotech, Inc. will post 6.14 EPS for the current fiscal year.
Krystal Biotech Profile
Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).
See Also
- Five stocks we like better than Krystal Biotech
- Quiet Period Expirations Explained
- After Gold Blast Soars Past $4,000, BofA Eyes $5,000 in 2026
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- Buyback Boom: 3 Companies Betting Big on Themselves
- Roth IRA Calculator: Calculate Your Potential Returns
- Analysts Flock to Upgrade DELL After Big AI-Server Guidance Boost
Want to see what other hedge funds are holding KRYS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Krystal Biotech, Inc. (NASDAQ:KRYS – Free Report).
Receive News & Ratings for Krystal Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Krystal Biotech and related companies with MarketBeat.com's FREE daily email newsletter.